News & Updates

Microbiome-derived deoxycholic acid (DCA) worsens portal hypertension by boosting TPH1-dependent 5-hydroxytryptamine (5-HT) biosynthesis, which activates portal vein smooth muscle cell contraction via HTR1A-GIRK3 signalling, a study has found.

Patients with chronic hepatitis B (CHB) infection who consume high levels of alcohol are at increased risk of hepatocellular carcinoma (HCC), as suggested in a retrospective study from China.

Use of aspirin after curative-intent treatment of colorectal cancer (CRC) liver metastases does not appear to improve disease-free survival and is even associated with reduced overall survival and more serious adverse events (AEs), according to the phase III ASAC trial

In patients with decompensated cirrhosis and sarcopenia, dietitian-supervised intensive nutritional therapy yielded greater improvements in skeletal muscle mass, strength, and physical performance compared with routine physician-led guideline-based dietary advice, as shown in a study.

Biochemical response (BR) rates do not differ between entecavir (ETV) and tenofovir alafenamide (TAF), but virologic (VR) and complete response (CR) rates are modestly higher with TAF, reveals a study.

Maintenance of mean arterial pressure between 70 and 75 mm Hg helps improve survival and kidney recovery in patients with decompensated cirrhosis and septic shock, suggests a study.

Advanced cardiovascular-kidney-metabolic (CKM) syndrome (stages 3 and 4) is associated with higher risks of all-cause and cardiovascular (CV) mortality at 20 years, according to a prospective study in Hong Kong.

Treatment with the thyroid hormone receptor β agonist ALG-055009 appears to yield substantial reductions in liver fat with no relevant safety issues in patients with metabolic dysfunction-associated steatohepatitis (MASH), according to a phase IIa study.

Glycosylated noncoding small RNAs (glycoRNAs) are present in human hepatocytes and liver tissues, showing a dysregulated expression in experimental steatosis models and in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a study has found.

Treatment with bulevirtide monotherapy for up to 144 weeks is safe, well tolerated, and effective in patients with chronic hepatitis D (CHD), a study has shown.